The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2016

Filed:

Apr. 29, 2005
Applicants:

Michael John Bradley Kutryk, Ontario, CA;

Robert J. Cottone, Jr., Davie, FL (US);

Stephen M. Rowland, Miami, FL (US);

Inventors:

Michael John Bradley Kutryk, Ontario, CA;

Robert J. Cottone, Jr., Davie, FL (US);

Stephen M. Rowland, Miami, FL (US);

Assignee:

OrbusNeich Medical, Inc., Fort Lauderdale, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61F 2/06 (2013.01); A61F 2/82 (2013.01); A61K 48/00 (2006.01); C12N 15/87 (2006.01); A61K 47/48 (2006.01); A61L 27/30 (2006.01); A61L 27/34 (2006.01); A61L 27/38 (2006.01); A61L 27/54 (2006.01); A61L 29/08 (2006.01); A61L 29/10 (2006.01); A61L 29/16 (2006.01); A61L 31/08 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01); C12N 5/071 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 47/48992 (2013.01); A61K 48/005 (2013.01); A61L 27/303 (2013.01); A61L 27/34 (2013.01); A61L 27/3808 (2013.01); A61L 27/54 (2013.01); A61L 29/085 (2013.01); A61L 29/103 (2013.01); A61L 29/16 (2013.01); A61L 31/084 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C12N 5/0692 (2013.01); A61K 35/12 (2013.01); A61L 2300/258 (2013.01); A61L 2300/416 (2013.01); A61L 2300/64 (2013.01); C12N 2510/00 (2013.01);
Abstract

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.


Find Patent Forward Citations

Loading…